Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics symbols : Akro save search
Ademi LLP Investigates Claims of Securities Fraud against Akero Therapeutics, Inc.
Published: 2024-04-02 (Crawled : 22:00) - prnewswire.com
PIK | $4.24 20.62% 66K
|
|
| O: -7.63%
H: 8.26%
C: 2.61%
MORF | $27.73 -3.55% -3.68% 330K
|
Health Technology
|
| O: -1.16%
H: 1.78%
C: 0.57%
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -0.73%
H: 1.16%
C: -0.13%
Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Published: 2024-03-08 (Crawled : 21:00) - globenewswire.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
| Email alert
Add to watchlist
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
| Email alert
Add to watchlist
offering therapeutics
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.16%
H: 5.27%
C: 0.81%
publication therapeutics study
Akero Therapeutics Announces Pricing of Public Offering of Common Stock - March 06, 2024
Published: 2024-03-06 (Crawled : 12:00) - biospace.com/
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: -2.65%
H: 1.36%
C: -1.28%
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 2.23%
H: 3.85%
C: -3.85%
offering therapeutics
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
Published: 2024-03-06 (Crawled : 03:00) - globenewswire.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: -2.65%
H: 1.36%
C: -1.28%
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 2.23%
H: 3.85%
C: -3.85%
offering therapeutics
Akero Therapeutics Announces Proposed Public Offering of Common Stock
Published: 2024-03-04 (Crawled : 21:00) - globenewswire.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: -0.94%
H: 2.19%
C: -0.07%
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -1.03%
H: 1.95%
C: -0.75%
offering therapeutics
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
Published: 2024-03-04 (Crawled : 11:00) - globenewswire.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 27.68%
H: 4.2%
C: -12.5%
week therapeutics study
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
Published: 2024-02-29 (Crawled : 13:00) - globenewswire.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 2.94%
H: 6.28%
C: -3.71%
efruxifermin topline week therapeutics results study
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-02-29 (Crawled : 12:00) - globenewswire.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 2.94%
H: 6.28%
C: -3.71%
business year update therapeutics financial results
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-03 (Crawled : 13:00) - globenewswire.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: -4.72%
conference therapeutics
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -0.87%
H: 0.0%
C: -3.17%
first efruxifermin program therapeutics
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-11-13 (Crawled : 12:00) - globenewswire.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -0.14%
H: 1.41%
C: 0.42%
business update therapeutics financial results
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023
Published: 2023-11-10 (Crawled : 14:00) - globenewswire.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: -1.26%
meeting liver therapeutics
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
Published: 2023-11-08 (Crawled : 12:00) - globenewswire.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: -2.96%
therapeutics
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
Published: 2023-10-17 (Crawled : 20:00) - globenewswire.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -0.21%
H: 0.77%
C: -4.32%
conference therapeutics nash
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins
Published: 2023-10-10 (Crawled : 11:00) - globenewswire.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -59.06%
H: 0.0%
C: -8.66%
liver fibrosis therapeutics results insulin nash
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
Published: 2023-10-09 (Crawled : 20:00) - globenewswire.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -59.06%
H: 0.0%
C: -8.66%
cirrhosis efruxifermin therapeutics results nash study
Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
Published: 2023-10-04 (Crawled : 12:00) - globenewswire.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.76%
H: 0.63%
C: -3.72%
lancet publication trial therapeutics results
Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
Published: 2023-08-31 (Crawled : 11:00) - globenewswire.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: -0.29%
H: 0.0%
C: 0.0%
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: -0.16%
H: 0.75%
C: 0.0%
therapeutics
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
Published: 2023-08-28 (Crawled : 11:00) - globenewswire.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 3.79%
H: 4.04%
C: 0.4%
report therapeutics results study
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.